Colorcon, a developer and supplier of film coating systems and excipients, has introduced its On-Dose Authentication capability to provide track and trace functionality for supply chain security. According to the company, the seamless integration of molecular taggants from Applied DNA Sciences (ADNAS) into an Opadry fully formulated film coating system reduces the risks associated with counterfeit and falsified medications entering the supply chain.
This first commercial offering is the culmination of extensive collaboration between Colorcon and ADNAS to help pharmaceutical companies enhance patient safety and reduce risk by using intelligent data and analytics gathered from authentication of the dosage form itself. By better understanding the vulnerabilities of a complex global supply chain, drug manufacturers can make informed decisions regarding distribution networks and deploy preventative measures to address counterfeiting and product diversion issues.
“With new guidelines from regulators and accessible technology, on-dose solutions provide a more robust and reliable means of identifying and deterring counterfeiting, verifying product authenticity, and ensuring product traceability,” said Ali Rajabi-Siahboomi, vice president and chief scientific officer, Colorcon. “Through extensive research and development, Colorcon has created a unique coating system to address this global problem.”
Kelly Boyer, general manager, film coatings, Colorcon, said, “On-dose authentication technology represents the next generation in pharmaceutical supply-chain security by providing a powerful tool for tracking product from plant to patient. By seamlessly enabling authentication, these digitized coatings confirm the quality and origin of medicines thereby safeguarding both patients and brands.”
This first commercial offering is the culmination of extensive collaboration between Colorcon and ADNAS to help pharmaceutical companies enhance patient safety and reduce risk by using intelligent data and analytics gathered from authentication of the dosage form itself. By better understanding the vulnerabilities of a complex global supply chain, drug manufacturers can make informed decisions regarding distribution networks and deploy preventative measures to address counterfeiting and product diversion issues.
“With new guidelines from regulators and accessible technology, on-dose solutions provide a more robust and reliable means of identifying and deterring counterfeiting, verifying product authenticity, and ensuring product traceability,” said Ali Rajabi-Siahboomi, vice president and chief scientific officer, Colorcon. “Through extensive research and development, Colorcon has created a unique coating system to address this global problem.”
Kelly Boyer, general manager, film coatings, Colorcon, said, “On-dose authentication technology represents the next generation in pharmaceutical supply-chain security by providing a powerful tool for tracking product from plant to patient. By seamlessly enabling authentication, these digitized coatings confirm the quality and origin of medicines thereby safeguarding both patients and brands.”
